Article info
Commentary
The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer
- Correspondence to Professor Donal J Brennan, UCD Gynaecological Oncology Group,Catherine McAuley Research Centre, UCD School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland; donal.brennan{at}ucd.ie
Citation
The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer
Publication history
- Received February 23, 2023
- Accepted February 27, 2023
- First published March 10, 2023.
Online issue publication
May 01, 2023
Article Versions
- Previous version (10 March 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.